| Bioactivity | BML-259 is a potent cyclin-dependent kinase 5 (Cdk5) inhibitor, with IC50s of 64 and 98 nM for Cdk5 and Cdk2, respectively[1]. | ||||||||||||
| Invitro | BML-259 (10 μM) protects large population of cells against non-Aβ component of Alzheimer's disease amyloid (NAC)-evoked cell death[2]. | ||||||||||||
| Name | BML-259 | ||||||||||||
| CAS | 267654-00-2 | ||||||||||||
| Formula | C14H16N2OS | ||||||||||||
| Molar Mass | 260.35 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Kaźmierczak A, et al. A novel mechanism of non-Aβ component of Alzheimer's disease amyloid (NAC) neurotoxicity. Interplay between p53 protein and cyclin-dependent kinase 5 (Cdk5). Neurochem Int. 2011;58(2):206-214. |